Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C.

@article{Patel2011OpenlabelAD,
  title={Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C.},
  author={Keyur A. Patel and Ravi Jhaveri and Jacob George and Guan Qiang and Christopher A. Kenedi and Kyle Brown and Charlotte E Cates and Amany Zekry and Hans L Tillmann and Lenzi Elliott and Rahki Kilaru and Janice Albrecht and Andrew Conrad and John McHutchison},
  journal={Journal of viral hepatitis},
  year={2011},
  volume={18 5},
  pages={331-7}
}
HMG CoA reductase inhibition suppresses in vitro HCV replication through depletion of cellular sterol proteins such as geranylgeraniol. Our aims were to prospectively evaluate the changes in serum and lipid fraction HCV RNA with Rosuvastatin in non-responder (NR) patients with CHC. A total of 11 patients with CHC genotype-1 received Rosuvastatin at 20 mg qd (weeks 0-4), 40 mg qd (weeks 5-12), with 4 week follow up. Lipid fractions were separated by a sucrose density gradient ultracentrifugation… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…